JNCCN-360

Editor:

James L. Mohler, MD

Advertisement

Advertisement

Sumit K. Subudhi, MD, PhD, on Managing Apalutamide Toxicities in Prostate Cancer

Howard I. Scher, MD, on Managing Enzalutamide Toxicities in Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: An Update on Treatment Recommendations

Recent

AUA 2019: Targeted Versus Systemic Biopsy for Diagnosing Prostate Cancer

ESTRO 2019: High-Dose Rate Monotherapy for Localized Prostate Cancer

Darolutamide Granted NDA and Priority Review in Nonmetastatic Castration-Resistant Prostate Cancer

Predicting Adverse Prostate Cancer Pathology With Genetic Assay

Published

Medical Literature

AR-V7 Assays and Treatment Outcomes in Castration-Resistant Prostate Cancer

Combining Approved Treatments in Metastatic Castration-Resistant Prostate Cancer

Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Duration of ADT With Radiation After Prostatectomy Depends on Risk Factors

Ongoing

Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Systemic Treatment of Prostate Cancer

Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care – Prostate Cancer

Current Approaches to the Treatment of Metastatic Castration-Resistant Prostate Cancer

Available

Clinical Trials

University of Nebraska

University of Wisconsin Carbone Cancer Center

Dana-Farber Cancer Institute

Siteman Cancer Center

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.